Membranoproliferative glomerulonephritis screening: Difference between revisions
Nazia Fuad (talk | contribs) |
Aditya Ganti (talk | contribs) |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Membranoproliferative glomerulonephritis}} | |||
{{CMG}} ; {{AE}} {{JSS}} | |||
==Overview== | ==Overview== | ||
There is insufficient evidence to recommend routine screening for MPN. | |||
==Screening== | |||
There is insufficient evidence to recommend routine screening for MPN. | |||
==References== | |||
{{reflist|2}} | |||
Latest revision as of 20:07, 6 August 2018
|
Membranoproliferative glomerulonephritis Microchapters |
|
Differentiating Membranoproliferative glomerulonephritis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Membranoproliferative glomerulonephritis screening On the Web |
|
American Roentgen Ray Society Images of Membranoproliferative glomerulonephritis screening |
|
Membranoproliferative glomerulonephritis screening in the news |
|
Directions to Hospitals Treating Membranoproliferative glomerulonephritis |
|
Risk calculators and risk factors for Membranoproliferative glomerulonephritis screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Jogeet Singh Sekhon, M.D. [2]
Overview
There is insufficient evidence to recommend routine screening for MPN.
Screening
There is insufficient evidence to recommend routine screening for MPN.